| 王海洋,范 云.EGFR TKIs耐药机制及其应对策略的研究进展[J].肿瘤学杂志,2017,23(5):366-371. |
| EGFR TKIs耐药机制及其应对策略的研究进展 |
| Research Progress on Mechanisms of Resistance and Treatment Approaches of EGFR-TKI |
| 投稿时间：2017-01-30 |
| DOI：10.11735/j.issn.1671-170X.2017.05.B002 |
|
 |
| 中文关键词: 肺癌 EGFR EGFR酪氨酸激酶抑制剂 耐药机制 |
| 英文关键词:lung cancer EGFR EGFR-TKIs resistance mechanism |
| 基金项目: |
|
| 摘要点击次数: 1727 |
| 全文下载次数: 520 |
| 中文摘要: |
| 摘 要：随着对肿瘤发病机制及其生物学行为的深入研究，分子靶向治疗成为目前治疗非小细胞肺癌( non-small cell lung cancer，NSCLC) 最具前景的研究领域。表皮生长因子受体酪氨酸激酶抑制剂( epidermal growth factor receptor tyrosine kinase inhibitor，EGFR-TKI) 可延长患者无进展生存期并明显提高患者生活质量，然而耐药已成为影响该类药物临床应用的最大障碍。全文就一代和三代EGFR-TKI的耐药机制与治疗策略的研究进展进行综述。 |
| 英文摘要: |
| Abstract：With deeper insights into the pathogenesis and biological behavior of cancer，molecular targeted therapy has become the most promising area in the studies of non-small cell lung cancer(NSCLC). The epidermal growth factor receptor tyrosine kinase inhibitor(EGFR-TKI) significantly improves the quality of life and prolongs progression-free survival of the patients，but the resistance to EGFR-TKI has emerged as the biggest obstacle to its application. This article updates the mechanisms of the resistance and treatment approaches of first-generation and third-generation EGFR-TKIs． |
|
在线阅读
查看全文 查看/发表评论 下载PDF阅读器 |